Close

Novo Nordisk (NVO) Files Semaglutide NDA with U.S. FDA as T2D Treatment

December 5, 2016 9:44 AM EST Send to a Friend
Novo Nordisk (NYSE: NVO) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login